和誉药业:ABSK141新药临床申请获美国FDA批准

和讯网
Dec 01

【和誉药业附属公司新药临床试验申请获美国FDA批准】12月1日,和誉药业公告,其附属公司上海和誉生物医药科技有限公司透露,口服小分子KRASG12D抑制剂ABSK141的新药临床试验申请,已获美国食品药品监督管理局批准。 ABSK141是口服、高活性、高选择性小分子KRASG12D抑制剂,用于治疗携带KRASG12D突变的晚期实体瘤患者。 此次获批的是开放标签I/II期临床研究,旨在评估...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10